- Home
- CRVS
as 07-26-2024 4:00pm EST
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BURLINGAME |
| Market Cap: | 111.3M | IPO Year: | 2016 |
| Target Price: | $5.75 | AVG Volume (30 days): | 138.1K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $2.60 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Corvus Pharmaceuticals Inc. (CRVS)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jones William Benton | CRVS | See Remarks | May 6 '24 | Buy | $1.73 | 20,000 | $34,624.00 | 153,773 | SEC Form 4 |
| MILLER RICHARD A MD | CRVS | President and CEO | May 6 '24 | Buy | $1.73 | 577,634 | $999,999.98 | 577,634 | SEC Form 4 |
Latest Corvus Pharmaceuticals Inc. News
CRVS Breaking Stock News: Dive into CRVS Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
Simply Wall St.
a month ago
Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) stock price dropped 12% last week; retail investors would not be happy
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
AFP
2 months ago
Bumrah delivers as India beat Pakistan in low-scoring thriller
AFP
2 months ago
Italy beat Bosnia in final Euros warm-up
AFP
2 months ago
Trump loyalists proud to support 'felon' at Las Vegas rally
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Compare CRVS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRVS Corvus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.